Trulicity OK'd for Primary, Secondary MACE Prevention

]]>(MedPage Today) -- The FDA expanded indications for the diabetes drug dulaglutide (Trulicity) to include major adverse cardiovascular event (MACE) risk reduction in adults with type 2 diabetes, drugmaker Eli Lilly announced--and not just for...